Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Comparison of losartan and amlodipine effects on the outcomes of patient with COVID‐19 and primary hypertension: A randomised clinical trial
Masoud Nouri‐Vaskeh, Niusha Kalami, Ramin Zand, et al.
International Journal of Clinical Practice (2021) Vol. 75, Iss. 6
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Molnupiravir: A new candidate for COVID‐19 treatment
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee
Pharmacology Research & Perspectives (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 114
Acute respiratory distress syndrome in COVID-19: possible mechanisms and therapeutic management
Anolin Aslan, Cynthia Aslan, Naime Majidi Zolbanin, et al.
Pneumonia (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 114
Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
Sonali R. Gnanenthiran, Claudio Borghi, Dylan Burger, et al.
Journal of the American Heart Association (2022) Vol. 11, Iss. 17
Open Access | Times Cited: 44
Seven days treatment with the angiotensin II type 2 receptor agonist C21 in hospitalized COVID-19 patients; a placebo-controlled randomised multi-centre double-blind phase 2 trial
Göran Tornling, Rohit Batta, Joanna C. Porter, et al.
EClinicalMedicine (2021) Vol. 41, pp. 101152-101152
Open Access | Times Cited: 35
Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial
Meg Jardine, Sradha Kotwal, Abhinav Bassi, et al.
BMJ (2022), pp. e072175-e072175
Open Access | Times Cited: 26
Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations
Lucia A. Méndez‐García, Galileo Escobedo, Alan Gerardo Minguer-Uribe, et al.
Frontiers in Cellular Neuroscience (2022) Vol. 16
Open Access | Times Cited: 24
Emerging Viral Infections and the Potential Impact on Hypertension, Cardiovascular Disease, and Kidney Disease
Solomiia Savedchuk, Rasha Raslan, Sarah Nystrom, et al.
Circulation Research (2022) Vol. 130, Iss. 10, pp. 1618-1641
Open Access | Times Cited: 21
All-solid-state paper-based potentiometric combined sensor modified with reduced graphene oxide (rGO) and molecularly imprinted polymer for monitoring losartan drug in pharmaceuticals and biological samples
Saad S. M. Hassan, Ayman H. Kamel, Mahmoud Abdelwahab Fathy
Talanta (2022) Vol. 253, pp. 123907-123907
Closed Access | Times Cited: 21
Effects of Renin–Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials
Juntao Yin, Chaoyang Wang, Xiaoyong Song, et al.
American Journal of Hypertension (2022) Vol. 35, Iss. 5, pp. 462-469
Open Access | Times Cited: 18
A Meta-Analysis of the Impact of Using Angiotensin-Converting Enzyme Inhibitors (ACEIs) or Angiotensin II Receptor Blockers (ARBs) on Mortality, Severity, and Healthcare Resource Utilization in Patients with COVID-19
Ruijuan Li, Jie Zhang, Liang Ren
Advances in respiratory medicine (2025) Vol. 93, Iss. 1, pp. 4-4
Open Access
Modulation of the Renin-Angiotensin System against COVID-19: A path forward?
Serge Camelo, Waly Dioh, J. Pedro Teixeira, et al.
International Journal of Infectious Diseases (2025), pp. 107867-107867
Open Access
Effects of Losartan on Patients Hospitalized for Acute Coronavirus Disease 2019: A Randomized Controlled Trial
Karen Tran, Pierre Asfar, Matthew P. Cheng, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 3, pp. 615-625
Closed Access | Times Cited: 3
Association of Amlodipine with the Risk of In-Hospital Death in Patients with COVID-19 and Hypertension: A Reanalysis on 184 COVID-19 Patients with Hypertension
Gwenolé Loas, Philippe van de Borne, Gil Darquennes, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 3, pp. 380-380
Open Access | Times Cited: 11
Incidence of Stroke in Randomized Trials of COVID-19 Therapeutics: A Systematic Review and Meta-Analysis
Sanjana Nagraj, Dimitrios Varrias, Gabriel Hernández Romero, et al.
Stroke (2022) Vol. 53, Iss. 11, pp. 3410-3418
Open Access | Times Cited: 11
The Effects of Different Classes of Antihypertensive Drugs on Patients with COVID-19 and Hypertension: A Mini-Review
Farnoosh Nozari, Nasrin Hamidizadeh
International Journal of Hypertension (2022) Vol. 2022, pp. 1-8
Open Access | Times Cited: 10
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
Innocent G. Asiimwe, Sudeep Pushpakom, Richard M. Turner, et al.
British Journal of Clinical Pharmacology (2022) Vol. 88, Iss. 8, pp. 3577-3599
Open Access | Times Cited: 10
Discovery of Chalcone-Based Hybrid Structures as High Affinity and Site-Specific Inhibitors against SARS-CoV-2: A Comprehensive Structural Analysis Based on Various Host-Based and Viral Targets
Mehdi Valipour, Silvia Di Giacomo, Antonella Di Sotto, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8789-8789
Open Access | Times Cited: 6
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
Matthew M.Y. Lee, Toru Kondo, Ross T. Campbell, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 10, Iss. 1, pp. 68-80
Open Access | Times Cited: 6
Pharmacotherapy for hypertensive urgency and emergency in COVID-19 patients
Fabio Angeli, Paolo Verdecchia, Gianpaolo Reboldi
Expert Opinion on Pharmacotherapy (2021) Vol. 23, Iss. 2, pp. 235-242
Open Access | Times Cited: 14
Update on Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) in SARS-CoV-2 Infection
Gwenolé Loas, Pascal Le Corre
Pharmaceuticals (2021) Vol. 14, Iss. 7, pp. 691-691
Open Access | Times Cited: 13
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials
Joseph Alexander Paguio, Bruce Adrian Casipit, Tara A John, et al.
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 3, pp. 219-226
Closed Access | Times Cited: 5
Renin–angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials
Chia Siang Kow, Long Chiau Ming, Syed Shahzad Hasan
Hypertension Research (2021) Vol. 44, Iss. 8, pp. 1042-1045
Open Access | Times Cited: 12
RAAS-Hemmung und darüber hinaus – Herz-Kreislauf-Medikation bei Patienten mit einem Risiko für oder Erkrankung durch COVID-19
Alexander Dutsch, Heribert Schunkert
Herz (2023) Vol. 48, Iss. 3, pp. 206-211
Open Access | Times Cited: 4
Comparison of the effects of losartan potassium and benazepril in the treatment of hypertensive patients with insulin resistance
Tingting Ma, Yangui Wang, Haixia Liu, et al.
Pakistan Journal of Medical Sciences (2024) Vol. 40, Iss. 8
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top